Framework Journal · one stock, one dated entry

Recorded 2025-12-31 · Permanent

Lixte Biotechnology Holdings Inc LIXT

Clears both ethical standards

An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.

In plain words · Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical and proton cancer therapy company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies.

The label
Distribution

read at $7.21

Lixte Biotechnology Holdings Inc holds its Distribution at $7.21.

PHINPOOPSC
  • PHPhase · the trend structure carries the Distribution label
  • INInsiders · no filings inside 60 days, left as found
  • POPositioning · no disclosures inside 60 days, left as found
  • OPOptions · no verdict drawn today, left as found
  • SCScreen · screen not yet scored
  • edge confirmed
  • edge broken
  • edge forming

Each arm is one independent read. Conviction is not a single call, it is how many edges converge.

The investor read · the season, not the day

As held on the ledger · 2025-12-31
PhaseDistribution · caution
Quantitative stateElevated stress, defensive posture warranted, held for 22 days
Price$7.21
ValuationN/A trailing · N/A forward price to earnings
Values screenNot scored · score 70.0
BetaN/A

The business, in plain words · what the numbers mean

The fundamentals · plain-English read
Profit margin0.0%
currently unprofitable
Market cap$125M
Employees3

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.

Plain-English interpretation of our own screen data. Analysis, not advice.

Related securities · others in LIXT's space worth a look

Screened names in the same industry · explore each on its own page.

The trader read · the latest dated commentary

The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 16.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bullish. Over the past year the shares are up 428%. Our forward projection puts the odds of a 10% gain over the next month near 39%. Entered 2026-08-04 · Distribution

The dated journal · newest first, never edited

2026-08-04 Distribution · changed $7.21 +16.5% Entry 4

The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 16.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bullish. Over the past year the shares are up 428%. Our forward projection puts the odds of a 10% gain over the next month near 39%.

2026-07-18 Markup $6.19 +0.0% Entry 3

The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bullish. Over the past year the shares are up 428%. Our forward projection puts the odds of a 10% gain over the next month near 39%.

2026-07-03 Markup $6.19 +0.0% Entry 2

The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.

2026-07-02 Markup $6.19 Entry 1

The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

What holding actually paid · price plus dividends

If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $5.15 +34.3% · $1,343 +34.3%
2 months $3.05 +126.7% · $2,267 +126.7%
3 months $3.24 +113.4% · $2,134 +113.4%
6 months $4.20 +64.6% · $1,646 +64.6%
1 year $1.31 +427.9% · $5,279 +427.9%
2 years $2.42 +185.7% · $2,857 +185.7%
3 years $5.19 +33.2% · $1,332 +33.2%
5 years $29.40 -76.5% · $235 -76.5%

Historical returns from market close data. Past performance does not guarantee future results.

This entry now belongs to the ledger. Whatever LIXT does next, these words stay.

Lixte Biotechnology Holdings Inc · LIXT · Distribution · $7.21
Recorded 2025-12-31 · before the outcome · scored mechanically

Get our weekly market brief free.